Albuterol

Summary

Albuterol (CHEMBL714) is an approved small-molecule bronchodilator agent (ATC R03AC02) targeting ADRB2; indicated across 30 conditions including chronic obstructive pulmonary disease and obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03AC02 (+1 more)
• Targets: 1 (ADRB2)
• Indications: 30 conditions
• Clinical trials: 296
• Chemistry: 239.31 Da · C13H21NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL714
Name	Albuterol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2083
ChEBI	CHEBI:2549
ATC	R03AC02, R03CC02
Molecular formula	C13H21NO3
Molecular weight	239.31
InChIKey	NDAUXUAQIAJITI-UHFFFAOYSA-N

SMILES: CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O

IUPAC name: 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol

ChEBI definition: A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a β-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Pharmacological roles (ChEBI): bronchodilator agent, β-adrenergic agonist.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Aerolin, Aerolin 400, Aerolin auto, Airomir, Airsalb, Albuterol, Asmasal clickhaler, Asmasal spacehaler, Asmaven, Asmavent, Cobutolin, Combivent

Parent form; salt/anhydrous children: CHEMBL1201026, CHEMBL1437301, CHEMBL1441059

Patent coverage: 17,920 distinct patent families (67,291 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 66,920 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRB2	β2-adrenoceptor	Partial agonist	7.7	0.4%	P07550

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor.

Bioactivity

ChEMBL activities: 26 potent at pChembl ≥ 5 of 27 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB2	9.96	EC50	0.11	nM	CHEMBL_ACT_24911223
Q8K4Z4	9.34	EC50	0.45	nM	CHEMBL_ACT_2688167
ADRB1	8.81	EC50	1.53	nM	CHEMBL_ACT_24911244
Q8K4Z4	8.04	EC50	9.1	nM	CHEMBL_ACT_2612963
Q8K4Z4	7.77	IC50	17	nM	CHEMBL_ACT_3294072
ADRB2	7.6	EC50	25.12	nM	CHEMBL_ACT_8007831
ADRB2	7.17	EC50	68	nM	CHEMBL_ACT_3294074
Q8K4Z4	6.96	Kd	109.7	nM	CHEMBL_ACT_15153057
ADRB2	6.7	EC50	199.5	nM	CHEMBL_ACT_6284209
ADRB2	6.66	Kd	220	nM	CHEMBL_ACT_19403986
ADRB2	6.62	AC50	240	nM	CHEMBL_ACT_25233833
Q8K4Z4	6.61	Kd	245.5	nM	CHEMBL_ACT_15153054
ADRB2	6.6	EC50	251	nM	CHEMBL_ACT_23194853
Q8K4Z4	6.57	EC50	268	nM	CHEMBL_ACT_2688169
ADRB2	6.29	Ki	510	nM	CHEMBL_ACT_2612950
Q28044	6.28	Kd	520	nM	CHEMBL_ACT_473805
ADRB2	6.25	Ki	557	nM	CHEMBL_ACT_7826268
Q28044	6.24	Kd	570	nM	CHEMBL_ACT_876348
ADRB2	6.09	IC50	810.2	nM	CHEMBL_ACT_7826267
ADRB2	6.01	IC50	980	nM	CHEMBL_ACT_2612944
Q8K4Z4	5.94	Kd	1160	nM	CHEMBL_ACT_2688174
ADRB1	5.93	EC50	1170	nM	CHEMBL_ACT_23194850
ADRB2	5.85	Kd	1400	nM	CHEMBL_ACT_19403975
ADRB2	5.74	Ki	1828	nM	CHEMBL_ACT_3294075
ADRB2	5.7	IC50	1995	nM	CHEMBL_ACT_8007816
ADRB2	5.31	AC50	4891	nM	CHEMBL_ACT_25123281

Target pathways

Aggregated over 1 target gene(s): ADRB2.

Top Reactome pathways

16 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	ADRB2
Membrane Trafficking	1	ADRB2
Signaling by GPCR	1	ADRB2
Class A/1 (Rhodopsin-like receptors)	1	ADRB2
Amine ligand-binding receptors	1	ADRB2
GPCR downstream signalling	1	ADRB2
Adrenoceptors	1	ADRB2
Metabolism of proteins	1	ADRB2
G alpha (s) signalling events	1	ADRB2
GPCR ligand binding	1	ADRB2
Vesicle-mediated transport	1	ADRB2
Deubiquitination	1	ADRB2
Ub-specific processing proteases	1	ADRB2
Post-translational protein modification	1	ADRB2
Cargo recognition for clathrin-mediated endocytosis	1	ADRB2
Clathrin-mediated endocytosis	1	ADRB2

Dominant GO biological processes

GO term	Targets
diet induced thermogenesis	1
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	1
regulation of sodium ion transport	1
transcription by RNA polymerase II	1
receptor-mediated endocytosis	1
smooth muscle contraction	1
cell surface receptor signaling pathway	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
endosome to lysosome transport	1
response to cold	1
positive regulation of cardiac muscle cell apoptotic process	1
negative regulation of cardiac muscle cell apoptotic process	1
positive regulation of bone mineralization	1
heat generation	1
negative regulation of multicellular organism growth	1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
chronic obstructive pulmonary disease	4	MONDO:0005002	EFO:0000341
obstructive lung disease	4	MONDO:0002267	HP:0006536

18 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
congestive heart failure	3	MONDO:0005009	EFO:0000373
Riley-Day syndrome	3	MONDO:0009131	Orphanet:1764
pulmonary arterial hypertension	3	MONDO:0015924	EFO:0001361
seasonal allergic rhinitis	3	MONDO:0005324	EFO:0003956
lung disorder	3	MONDO:0005275	EFO:0003818
pulmonary hypertension	3	MONDO:0005149	MONDO:0005149
heart failure	3	MONDO:0005252	EFO:0003144
pulmonary edema	2	MONDO:0006932	EFO:1001134
bronchiolitis	2	MONDO:0002465	HP:0011950
status asthmaticus	2	MONDO:0004766	EFO:0008590
respiratory failure	2	MONDO:0021113	EFO:0009686
allergic disease	2	MONDO:0005271	MONDO:0005271
spinal cord injury	2	MONDO:0043797	MONDO:0043797
congenital myasthenic syndrome	1	MONDO:0018940	Orphanet:590
idiopathic pulmonary fibrosis	1	MONDO:0800504	EFO:0000768
diabetes mellitus	1	MONDO:0005015	EFO:0000400
major depressive disorder	1	MONDO:0002009	MONDO:0002009
lymphangioleiomyomatosis	1	MONDO:0011705	MONDO:0011705

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 296.

Phase distribution

Phase	Trials
PHASE3	80
PHASE4	74
Not specified	70
PHASE2	36
PHASE1	28
EARLY_PHASE1	4
PHASE2/PHASE3	2
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02797275	PHASE4	ACTIVE_NOT_RECRUITING	Secondhand Smoke Respiratory Health Study
NCT06152653	PHASE4	RECRUITING	The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
NCT06422689	PHASE4	ACTIVE_NOT_RECRUITING	Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
NCT00070707	PHASE4	COMPLETED	Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
NCT00272753	PHASE4	COMPLETED	Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
NCT00315744	PHASE4	COMPLETED	Viapaed Study In Children And Adolescents With Asthma
NCT00354354	PHASE4	COMPLETED	Bronchodilators and Oxygen Kinetics With Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00363480	PHASE4	COMPLETED	Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data
NCT00385359	PHASE4	UNKNOWN	A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control
NCT00388882	PHASE4	COMPLETED	Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
NCT00393367	PHASE4	COMPLETED	Budesonide Inhalation Suspension for Acute Asthma in Children
NCT00440245	PHASE4	COMPLETED	Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
NCT00487773	PHASE4	COMPLETED	Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma
NCT00783250	PHASE4	TERMINATED	Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00830882	PHASE4	WITHDRAWN	Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol
NCT00831376	PHASE4	COMPLETED	Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol
NCT00900874	PHASE4	UNKNOWN	Rapid Onset Action of Salbutamol Versus Formoterol
NCT00911651	PHASE4	COMPLETED	Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00940927	PHASE4	COMPLETED	Dose-response of Albuterol in Asthmatics
NCT01091337	PHASE4	COMPLETED	Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room
NCT01151579	PHASE4	COMPLETED	Effect of Nebulized Bronchodilators on Heart Rate
NCT01253473	PHASE4	COMPLETED	Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)
NCT01338311	PHASE4	COMPLETED	Salbutamol Tolerance Onset
NCT01471340	PHASE4	COMPLETED	A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)
NCT01691482	PHASE4	COMPLETED	A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
NCT01721291	PHASE4	COMPLETED	Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
NCT01903785	PHASE4	COMPLETED	Salbutamol, Pharmacogenetics and Breathing Mechanics
NCT01907334	PHASE4	COMPLETED	Dose-Response of Salmeterol in Children
NCT01922271	PHASE4	COMPLETED	Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01951378	PHASE4	TERMINATED	Comparison of Nebulizers in ED in Pediatric Asthma Patients
NCT01978418	PHASE4	UNKNOWN	Inhaled Salbutamol in Elective Caesarean Section
NCT02103374	PHASE4	COMPLETED	Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State
NCT02182713	PHASE4	COMPLETED	Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm
NCT02233803	PHASE4	COMPLETED	A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma
NCT02235428	PHASE4	TERMINATED	Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children
NCT02257372	PHASE4	COMPLETED	A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02275052	PHASE4	COMPLETED	A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT02319564	PHASE4	WITHDRAWN	Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children
NCT02371629	PHASE4	COMPLETED	A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
NCT02405598	PHASE4	COMPLETED	Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
NCT02584738	PHASE4	UNKNOWN	Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation
NCT02654145	PHASE4	COMPLETED	Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
NCT02799784	PHASE4	COMPLETED	An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
NCT02877537	PHASE4	COMPLETED	Measurement of Respiratory Admittance for Pediatric Asthma Diagnosis
NCT02914652	PHASE4	COMPLETED	The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.
NCT03044938	PHASE4	COMPLETED	Acute Effect of Salbutamol on Heart Rate and Blood Pressure During Exercise in Patients With Moderate or Severe Asthma and Healthy Subjects
NCT03199976	PHASE4	TERMINATED	Efficacy of Intermittent Tiotropium in Early Childhood Wheezing
NCT03333395	PHASE4	COMPLETED	Nebulized Heparin and Salbutamol in Mechanically Ventilated Patients With AECOPD
NCT03363191	PHASE4	WITHDRAWN	The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
NCT03380429	PHASE4	COMPLETED	A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects
NCT03405090	PHASE4	COMPLETED	Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators
NCT03474081	PHASE4	COMPLETED	A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03478683	PHASE4	COMPLETED	A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03478696	PHASE4	COMPLETED	A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03493503	PHASE4	COMPLETED	Status Asthmaticus on the PICU; Intravenous Salbutamol
NCT03822637	PHASE4	TERMINATED	The Effect of NAC on Lung Function and CT Mucus Score
NCT03880903	PHASE4	UNKNOWN	Hypertonic Saline Inhalation in Acute Bronchiolitis
NCT03890666	PHASE4	COMPLETED	A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
NCT03924635	PHASE4	COMPLETED	An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
NCT04012138	PHASE4	COMPLETED	Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia
NCT04184609	PHASE4	WITHDRAWN	Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes
NCT04207840	PHASE4	COMPLETED	Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
NCT04276233	PHASE4	COMPLETED	Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
NCT04584034	PHASE4	WITHDRAWN	Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial
NCT04606394	PHASE4	COMPLETED	Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
NCT04677959	PHASE4	COMPLETED	A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
NCT04750603	PHASE4	COMPLETED	Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents
NCT05087693	PHASE4	COMPLETED	Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)
NCT05173584	PHASE4	UNKNOWN	Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.
NCT05667727	PHASE4	COMPLETED	The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome
NCT06036823	PHASE4	COMPLETED	5 Versus 10 Units of Insulin in Hyperkalemia Management
NCT06158893	PHASE4	UNKNOWN	Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy
NCT06563102	PHASE4	COMPLETED	Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
NCT06918418	PHASE4	COMPLETED	A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children
NCT05527704	PHASE3	ACTIVE_NOT_RECRUITING	the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)
NCT06471257	PHASE3	RECRUITING	A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06473779	PHASE3	ACTIVE_NOT_RECRUITING	Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06618105	PHASE3	NOT_YET_RECRUITING	Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd
NCT06946264	PHASE3	RECRUITING	Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features
NCT00000577	PHASE3	WITHDRAWN	Asthma Clinical Research Network (ACRN)
NCT00064389	PHASE3	COMPLETED	Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma
NCT00144846	PHASE3	COMPLETED	Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children
NCT00308685	PHASE3	COMPLETED	Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
NCT00382889	PHASE3	COMPLETED	As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma
NCT00384189	PHASE3	COMPLETED	A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
NCT00497523	PHASE3	COMPLETED	Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms
NCT00528723	PHASE3	COMPLETED	Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
NCT00550550	PHASE3	COMPLETED	Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
NCT00562159	PHASE3	COMPLETED	Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
NCT00577655	PHASE3	COMPLETED	Albuterol HFA MDI in Pediatric Participants With Asthma
NCT00588406	PHASE3	COMPLETED	Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.
NCT00633919	PHASE2/PHASE3	COMPLETED	Efficacy of SLITone in House Dust Mite Allergic Patients
NCT00634517	PHASE3	TERMINATED	4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
NCT00634829	PHASE3	TERMINATED	Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction
NCT00646009	PHASE3	COMPLETED	Symbicort Onset of Action 2
NCT00646620	PHASE3	COMPLETED	Symbicort Onset of Action 1
NCT00669617	PHASE3	COMPLETED	Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00685126	PHASE3	COMPLETED	Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)
NCT00685425	PHASE3	COMPLETED	Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol
NCT00861926	PHASE3	COMPLETED	Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 21 clinical and 59 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

188 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
ACEBUTOLOL	ChEMBL	Phase 4 (approved)	ADRB2
ADENOSINE	ChEMBL	Phase 4 (approved)	ADRB2
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRB2
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRB2
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRB2
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
ATENOLOL	ChEMBL	Phase 4 (approved)	ADRB2
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRB2
BETAXOLOL	ChEMBL	Phase 4 (approved)	ADRB2
BISOPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRB2
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	ADRB2
CARTEOLOL	ChEMBL	Phase 4 (approved)	ADRB2
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRB2
CELIPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	ADRB2
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRB2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRB2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
CLOZAPINE	ChEMBL	Phase 4 (approved)	ADRB2
DARIFENACIN	ChEMBL	Phase 4 (approved)	ADRB2
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	ADRB2
DIPIVEFRIN	ChEMBL	Phase 4 (approved)	ADRB2
DOBUTAMINE	ChEMBL	Phase 4 (approved)	ADRB2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRB2
DOPAMINE	ChEMBL	Phase 4 (approved)	ADRB2
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRB2
ELAGOLIX	ChEMBL	Phase 4 (approved)	ADRB2
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
EPINEPHRINE BITARTRATE	ChEMBL	Phase 4 (approved)	ADRB2
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRB2
ESMOLOL	ChEMBL	Phase 4 (approved)	ADRB2
FENOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	ADRB2
FORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRB2
INDACATEROL	ChEMBL	Phase 4 (approved)	ADRB2
ISOETHARINE	ChEMBL	Phase 4 (approved)	ADRB2
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	ADRB2
LABETALOL	ChEMBL	Phase 4 (approved)	ADRB2
LEVOBUNOLOL	ChEMBL	Phase 4 (approved)	ADRB2
LEVOSALBUTAMOL	ChEMBL	Phase 4 (approved)	ADRB2
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	ADRB2
LOPERAMIDE	ChEMBL	Phase 4 (approved)	ADRB2
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRB2
MEBEVERINE	ChEMBL	Phase 4 (approved)	ADRB2
METAPROTERENOL	ChEMBL	Phase 4 (approved)	ADRB2
METOPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	ADRB2
MONTELUKAST	ChEMBL	Phase 4 (approved)	ADRB2
NADOLOL	ChEMBL	Phase 4 (approved)	ADRB2
NEBIVOLOL	ChEMBL	Phase 4 (approved)	ADRB2
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	ADRB2
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRB2
OLANZAPINE	ChEMBL	Phase 4 (approved)	ADRB2
OXPRENOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PAROXETINE	ChEMBL	Phase 4 (approved)	ADRB2
PERPHENAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PHENYLEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
PIMAVANSERIN	ChEMBL	Phase 4 (approved)	ADRB2
PIMOZIDE	ChEMBL	Phase 4 (approved)	ADRB2
PINDOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PRACTOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PRENYLAMINE	ChEMBL	Phase 4 (approved)	ADRB2
PRIMAQUINE	ChEMBL	Phase 4 (approved)	ADRB2
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PROPAFENONE	ChEMBL	Phase 4 (approved)	ADRB2
PROPRANOLOL	ChEMBL	Phase 4 (approved)	ADRB2
RANOLAZINE	ChEMBL	Phase 4 (approved)	ADRB2
REBOXETINE	ChEMBL	Phase 4 (approved)	ADRB2
RIBOFLAVIN 5’-PHOSPHATE	ChEMBL	Phase 4 (approved)	ADRB2
RIFAMPIN	ChEMBL	Phase 4 (approved)	ADRB2
RIFAXIMIN	ChEMBL	Phase 4 (approved)	ADRB2
RIMEGEPANT	ChEMBL	Phase 4 (approved)	ADRB2
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRB2
RITODRINE	ChEMBL	Phase 4 (approved)	ADRB2
SALMETEROL	ChEMBL	Phase 4 (approved)	ADRB2
SALMETEROL XINAFOATE	ChEMBL	Phase 4 (approved)	ADRB2
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRB2
SOTALOL	ChEMBL	Phase 4 (approved)	ADRB2
SUNITINIB	ChEMBL	Phase 4 (approved)	ADRB2
TAMOXIFEN	ChEMBL	Phase 4 (approved)	ADRB2
TAMSULOSIN	ChEMBL	Phase 4 (approved)	ADRB2
TEGASEROD	ChEMBL	Phase 4 (approved)	ADRB2
TERBUTALINE	ChEMBL	Phase 4 (approved)	ADRB2
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRB2
TIMOLOL	ChEMBL	Phase 4 (approved)	ADRB2
TIOCONAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
TOLTERODINE	ChEMBL	Phase 4 (approved)	ADRB2
TOLVAPTAN	ChEMBL	Phase 4 (approved)	ADRB2
VALDECOXIB	ChEMBL	Phase 4 (approved)	ADRB2
VILANTEROL	ChEMBL	Phase 4 (approved)	ADRB2